Oncolyze
OperatingONCOLYZE
Biotech · Biotech
Biotech company aiming to treat cancer by exploding cancer cells
Financials
FY2021–FY2023 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Cap table
Share counts as of Jun 30, 2023| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| preferred stockpreferred | 173,260 | — | 10.6% | — |
| Common Stock | 1,468,448 | — | 89.5% | $0.0035May 2022 |
| Total | 1,641,708 | 100% |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- John Abeles221M (15021.5%) May 2022 → 221K (17432.0%) Feb 2023
- Steven J. Evans467M (31831.8%) May 2022 → 467K (36940.0%) Feb 2023
Principal holders% as the filing states it, Oct 26, 2023
- Steven J. Evans467,291 Common Stock19.3%of company
- John Abeles220,515 Common Stock15.5%of company
- Everyone else (not named in filings)65.3%
Sold to the crowd
- Reg A+ · May 2022378,227,000 shares at $0.0035 in today's terms · sold as 378,227 shares at $3.52; since then a 1000-for-1 split (Feb 2023)$1.3M· 601 investors
- Reg CF · Mar 2023$1.1M· 738 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
8 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 16 filings on EDGAR- Form 1-ZMar 1, 20240001104659-24-029789EDGAR
- Form 1-UFeb 29, 20240001104659-24-029225EDGAR
- Form 1-KOct 26, 20230001104659-23-111779EDGAR
- Form 1-SAMar 30, 20230001104659-23-038530EDGAR
- Form 253G2Mar 20, 20230001104659-23-034401EDGAR
- Form QUALIFMar 20, 20239999999994-23-000119EDGAR
- Form 1-A POSMar 7, 20230001104659-23-029509EDGAR
- Form 1-A POSFeb 10, 20230001104659-23-018638EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.